| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3534 | Myra-a | Novel inducer of apoptosis in a Myc-dependent manner, inhibiting Myc-driven transformation and disrupting MYC-Max interaction |
|
| DCC3535 | Myrtucommulone | Inhibitor of the chaperonin activity of HSP60, correlating to LONP and LRP130 aggregation |
|
| DCC3536 | Myxopyronin A | Bacterial RNA polymerase (RNAP) inhibitor |
|
| DCC3537 | Mzp-54 | Novel potent and selective PROTAC degrader of BRD3/4 |
|
| DCC3538 | N,n-dimethylsphingosine | Competitive inhibitor of both SPHK1 and SPHK2 |
|
| DCC3539 | n00236460 | Glucokinase activator (GKA) |
|
| DCC3540 | N6-allyladenosine | Novel RNA labeling probe through both metabolic and enzyme-assisted manners |
|
| DCC3541 | N6-methyl-d3-adenosine | Deuterium labeled m6A used in important m6A physiological pathways related studies |
|
| DCC3542 | Na-aaf | Alkylating agent, forming DNA adducts at the C-8 position in guanine, resulting in single strand breaks, demonstrating carcinogenic action |
|
| DCC3543 | Nabiximols | Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS)-related moderate to severe spasticity |
|
| DCC3544 | N-acetylloline | Derivative of loline |
|
| DCC3545 | N-adamantanylglycinamide Hbr | Novel antiviral agent against the replication of influenza virus A/H3N2 subtype in Madin-Darby canine kidney (MDCK) cells |
|
| DCC3546 | Nadide | Coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage |
|
| DCC3547 | Nadph Tetrasodium Salt | Electron donor and cofactor for many redox enzymes including nitric oxide synthetase |
|
| DCC3548 | Nafoxidine | Partial estrogen antagonist, inhibiting angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), inducing oxidative stress, protein kinase C and calcium signaling |
|
| DCC3549 | Nag-26 | Novel potent full agonist for orexin receptor |
|
| DCC3550 | Nai003 | Novel highly selective antibacterial agent against Propionibacterium acnes |
|
| DCC3551 | Nalbuphine Hydrochloride | Mixed agonist/antagonist opioid modulator, binding with high affinity to the MOR and KOR, and having relatively low affinity for the DOR |
|
| DCC3552 | Naph-o2 | Novel fluorescent probe for detection of endogenously produced Naph-O2˙– in living cells and tissues |
|
| DCC3553 | Naphthyridine-azaquinolone | Novel repeat-structure-specific DNA ligand, specifically binding slipped-CAG DNA intermediates of expansion mutations |
|
| DCC3554 | Naphyrone Hydrochloride | Triple reuptake inhibitor |
|
| DCC3555 | Napi2b Inhibitor 15 | Novel Gut-Restricted Inhibitor of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia |
|
| DCC3556 | Napitane Mesylate | Antagonist of alpha-2 adrenergic receptors and inhibitor of the neuronal uptake of norepinephrine |
|
| DCC3557 | Napsagatran | Inhibitor of extrinsic and intrinsic thrombin generation, inhibiting clot-bound and free (fluid-phase thrombin) |
|
| DCC3558 | N-arachidonoyl Taurine | Activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 |
|
| DCC3559 | Nargenicin | Natural DnaE1 blocker, inducing a DNA damage response in Mycobacterium tuberculosis (Mtb) and inhibiting growth by blocking the replicative DNA polymerase, DnaE1 |
|
| DCC3560 | Tylophorine | Potent suppressor of inducible nitric oxide synthase (iNOS; NOS II) |
|
| DCC3561 | Nav1.1-in-b | Novel selective NaV1.1 inhibitor, reducing visceral hypersensitivity |
|
| DCC3562 | Nav1.7 Blocker-13 | Novel selective blocker of NaV1.7 with little affinity for NaV 1.2, 1.3, or 1.6, being more potent at human vs guinea pig NaV1.7 |
|
| DCC3563 | Nav1.7 Blocker-24 | Potent and selective blocker of voltage-gated Nav1.7 sodium channels |
|
